Search

In Stock

Buy Yupelri (revefenacin) Online

DISEASE INDICATIONS: Chronic Obstructive Pulmonary Disease

MANUFACTURER: Theravance Biopharma

USAGE: Oral

MEDICINE APPROVED BY:

Food and Drug Administration (FDA)

Yupelri is a pharmaceutical medication used to treat chronic obstructive pulmonary disease (COPD), a chronic respiratory condition characterized by difficulty breathing, coughing, and wheezing.

This product is currently out of stock and unavailable.

Compare

Yupelri is a pharmaceutical medication used to treat chronic obstructive pulmonary disease (COPD), a chronic respiratory condition characterized by difficulty breathing, coughing, and wheezing. Specifically, Yupelri is a long-acting muscarinic antagonist (LAMA) bronchodilator that helps relax and widen the airways in the lungs, making it easier for individuals with COPD to breathe.

Here is a detailed description of Yupelri:

Active Ingredient:

  • Revefenacin: Revefenacin is the active ingredient in Yupelri. It belongs to a class of medications known as long-acting muscarinic antagonists (LAMAs). LAMAs work by blocking the action of acetylcholine, a neurotransmitter that can cause bronchoconstriction (narrowing of the airways). By doing so, revefenacin helps relax and open the air passages in the lungs, allowing for improved airflow and reduced COPD symptoms.

Dosage Forms:

Yupelri is typically available in the form of a solution for inhalation, which is administered using a nebulizer device. This nebulized solution allows the medication to be inhaled into the lungs effectively.

Indications:

Yupelri is indicated for the maintenance treatment of COPD in adults. It is used to manage and control COPD symptoms, such as shortness of breath and wheezing, and to improve lung function.

Usage:

The dosing and administration of Yupelri are determined by a healthcare provider. It is generally taken once daily as prescribed through a nebulizer device. Patients should follow their healthcare provider’s instructions carefully to ensure proper usage.

Benefits:

Yupelri helps manage COPD by relaxing the airways and reducing bronchoconstriction. This leads to improved lung function, reduced respiratory symptoms, and enhanced overall quality of life for individuals with COPD.

Precautions:

Before starting Yupelri, patients should consult with a healthcare provider. They should disclose any allergies, medical conditions, or other medications they are taking, as these factors can affect the safety and efficacy of the medication. Additionally, patients should be aware of potential side effects and follow their healthcare provider’s guidance for managing them.

Side Effects:

Common side effects of Yupelri may include headache, cough, and dry mouth. Less common side effects can include urinary tract infections and back pain. Patients should discuss any side effects or concerns with their healthcare provider.

In conclusion, Yupelri (revefenacin) is a medication used for the maintenance treatment of COPD in adults. It is a long-acting muscarinic antagonist (LAMA) bronchodilator that helps relax and open the airways, making it easier to breathe and reducing COPD symptoms. Patients should use it as directed by their healthcare provider and be aware of potential side effects and precautions associated with its use.

Package

175 μg/3 mL

Reviews

There are no reviews yet.

Write a review

Your email address will not be published. Required fields are marked *

Bestsellers

Buy Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) Online

$755.34
(0 Reviews)
DISEASE INDICATIONS: Chronic Obstructive Pulmonary Disease, Asthma MANUFACTURER: GlaxoSmithKline USAGE: Oral MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Pharmaceuticals and Medical Devices Agency (PMDA)   It is used for the management of chronic obstructive pulmonary disease (COPD), a chronic respiratory condition characterized by breathing difficulties, coughing, and wheezing. This medication is designed to provide comprehensive treatment for COPD by addressing various aspects of the disease.

Buy Symkevi (tezacaftor/ivacaftor) Online

$5,729.85
(0 Reviews)
DISEASE INDICATIONS: Cystic Fibrosis MANUFACTURER: Vertex Pharmaceuticals (Europe) Ltd USAGE: Oral MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Symkevi is specifically designed to address the underlying genetic defect in individuals with CF who have specific responsive mutations.

Buy Yupelri (revefenacin) Online

(0 Reviews)
DISEASE INDICATIONS: Chronic Obstructive Pulmonary Disease MANUFACTURER: Theravance Biopharma USAGE: Oral MEDICINE APPROVED BY: Food and Drug Administration (FDA) Yupelri is a pharmaceutical medication used to treat chronic obstructive pulmonary disease (COPD), a chronic respiratory condition characterized by difficulty breathing, coughing, and wheezing.

Buy Tezspire (tezepelumab-ekko) Online

$6,696.25
(0 Reviews)
DISEASE INDICATIONS: Asthma MANUFACTURER: Amgen / AstraZeneca AB USAGE: Subcutaneous MEDICINE APPROVED BY: Food and Drug Administration (FDA)   Tezspire (tezepelumab-ekko) is a prescription medication that belongs to the drug class of monoclonal antibodies. It is used to treat severe asthma in adults and children 12 years of age and older whose condition cannot be managed by their existing asthma medication. Tezspire is the first and only biologic approved for severe asthma without phenotypic or biomarker limitations.

Buy Trikafta (elexacaftor/tezacaftor/ivacaftor; ivacaftor) Online

From $39,106.10
(0 Reviews)
DISEASE INDICATIONS: Cystic Fibrosis MANUFACTURER: Vertex Pharmaceuticals Incorporated USAGE: Oral MEDICINE APPROVED BY: Food and Drug Administration (FDA)   Trikafta is designed to address the underlying genetic mutations in individuals with CF and has been shown to significantly improve lung function and overall health in many patients.

Buy Orkambi (lumacaftor/ivacaftor) Online

From $10,806.14
(0 Reviews)
DISEASE INDICATIONS: Cystic Fibrosis MANUFACTURER: Vertex Pharmaceuticals (Europe) Ltd USAGE: Oral MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Therapeutic Goods Administration (TGA) This medication is designed to address the underlying cause of CF in individuals who have two copies of the F508del mutation in the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) gene, which is a common genetic mutation associated with CF.

Buy Symdeko (tezacaftor / ivacaftor) Online

$39,418.95
(0 Reviews)
DISEASE INDICATIONS: Cystic Fibrosis MANUFACTURER: Vertex Pharmaceuticals (Europe) Ltd USAGE: Oral MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) , Symdeko is indicated for the treatment of patients with CF who have specific genetic mutations that are responsive to these medications. This combination therapy addresses the underlying cause of CF by improving the function of the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) protein, which is often dysfunctional in CF patients.

Back to Top
Product has been added to your cart